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2451of mortality in the trial (5 in the control group vs. 2 in the
intervention group) and a major contributor to reducing the
LVEF (patients who survived a septic episode experienced
a mean decrease in LVEF of 4.6  9 points, compared with
a decrease of 0.6  6 points in patients without sepsis
(p ¼ 0.04). Additionally, enalapril and carvedilol did not
show any statistically signiﬁcant difference in reducing the
incidence of heart failure or preventing the reduction in
LVEF >10% (p ¼ 0.22). This leaves us with 2 possibilities:
either 1) enalapril/carvedilol was not effective in preventing
LVSD in patients undergoing high-dose chemotherapy; or
2) enalapril/carvedilol might be effective in preventing heart
failure in certain subgroups of patients (e.g., those with ele-
vated troponin levels after chemotherapy). Larger random-
ized controlled trials are needed to answer these questions.*Harsh Golwala, MD
*Williams Pavilion, 1130
P. O. Box 26901
Oklahoma City, Oklahoma 73190
E-mail: harsh-golwala@ouhsc.edu
http://dx.doi.org/10.1016/j.jacc.2013.06.059REFERENCES
1. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for
preventing chemotherapy-induced left ventricular systolic dysfunction in
patients with malignant hemopathies: the OVERCOME trial (Prevention
of Left Ventricular DysfunctionWith Enalapril and Carvedilol in Patients
Submitted to Intensive Chemotherapy for the Treatment of Malignant
Hemopathies). J Am Coll Cardiol 2013;61:2355–62.
2. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose
chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-
converting enzyme inhibition. Circulation 2006;114:2474–81.Enalapril and Carvedilol for
Preventing Chemotherapy-
Induced Left Ventricular
Systolic DysfunctionWe read with great interest the article by Bosch et al. (1). We
congratulate the authors for their work, which sheds new light on
the potential for preventing cardiotoxic effects of anticancer ther-
apies. However, there are a few aspects that, in our opinion, need
clariﬁcation.
First, carvedilol is not only a beta-blocker, but also an antioxi-
dant agent. It has been proven that such antioxidant effects of
carvedilol play a crucial role in protecting cardiomyocytes from the
cardiotoxic effect of anthracyclines (2), and therefore, this should be
taken into account when the results of the study by Bosch et al. (1)
are analyzed.
Second, we noted that 8 patients (18%) in the control group were
hypertensive. We would like to underline that hypertension has to
be treated in all patients undergoing chemotherapy, and mostimportantly, angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers and beta-blockers should be part of
the therapeutic regimen. It is recommended that patients switch
from other drug classes to these agents before the start of chemo-
therapy (3).
Third, we believe that in the setting of high-dose chemotherapy
in very frail patients, the greatest effort should be put forth to
prevent, not only cardiotoxicity, but also any condition that may
hamper the correct execution of the planned chemotherapy. The
study protocol by Bosch et al. (1) provided that enalapril and car-
vedilol had to be started simultaneously with dose titrations every
3 to 6 days. Even if the association between ACE inhibitors and
beta-blockers is highly recommended in heart failure, practice
guidelines suggest that ACE inhibitor therapy should be started
ﬁrst, quickly followed by beta-blocker therapy, and recommend
waiting 1 to 2 weeks before increasing doses (4). Bosch et al. (1)
reported that in their hands the ACE inhibitor and beta-blocker
combined therapy was safe and that only 6 patients stopped car-
vedilol, enalapril, or both. However, we believe that the protocol of
the OVERCOME (Prevention of Left Ventricular Dysfunction
With Enalapril and Carvedilol in Patients Submitted to Intensive
Chemotherapy for the Treatment of Malignant Hemopathies) trial
might be a “double-edged sword”: although the protocol reduced
the risk of cardiotoxicity, it also increased the risk that patients
could not receive the optimal chemotherapy regimen due to adverse
effects, such as severe and/or symptomatic hypotension, which may
inﬂuence both patient’s compliance and physician’s evaluation.
Accordingly, we believe that this approach should be tested in
a larger number of patients and should be taken into consideration
only when there is strong cooperation between oncologists and
cardiologists.
Fourth, Bosch et al. (1) found that the combined treatment
with enalapril and carvedilol did not prevent troponin elevation
and that troponin elevation was not predictive of left ventricular
dysfunction. This ﬁnding is very important because it is in sharp
contrast to many studies that have demonstrated that troponin is
a tool for early identiﬁcation, assessment, and monitoring of an-
ticancer drug–induced cardiac injury. These studies have inﬂu-
enced the development of the European Society for Medical
Oncology Clinical Practice Guidelines that suggest evaluating
troponin serum levels during high-dose chemotherapy for the
early identiﬁcation of patients at risk of developing cardiac dys-
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for Preventing Chemotherapy-Induced
Left Ventricular Systolic Dysfunction in
Patients With Malignant HemopathiesWe thank Dr. Golwala and Dr. Spallarossa and colleagues for their
interest in our study. Both ask about the lack of association found
in our study (1) between troponin elevation and beneﬁt from
pharmacological intervention. The value of troponins to predict left
ventricular systolic dysfunction (LVSD) has been reported with
anthracyclines but not with other drugs (2). However, we do
not believe that our results are contradictory to those of Cardinale
et al. (3); differences in the patient population, intensity and type
of chemotherapy, and protocol design of both studies may account
for their different results. Cardinale et al. included only patients
with positive troponin levels 1 month after treatment, selecting
a population at a particularly high risk for developing a marked
drop in left ventricular ejection fraction (LVEF) (43% in their
control group), whereas we enrolled all incoming patients. In our
study, 10 of the 11 patients with positive troponin levels had acute
leukemia, a subgroup of patients that received anthracyclines and
a more intense chemotherapy regimen and in whom we observed
a marked effect of the intervention. Large randomized trials are
needed to determine whether a strategy of primordial prevention
with cardioprotective drugs to all patients is more effective than
a troponin-directed strategy.
Dr. Golwala questions the value of the results of the intervention
on a secondary endpoint of the study, the combined endpoint of
mortality, heart failure, and signiﬁcant LVSD, due to the potential
confounding factor of sepsis. As discussed in the paper, because
two-thirds of all deaths were related to sepsis, it is difﬁcult to
elucidate whether enalapril and carvedilol could have inﬂuenced
mortality. However, survivors of sepsis had a lower LVEF, and this
condition is a well-known determinant of mortality. Other factorsshould be considered because 8 of the 13 patients who survived
a septic episode had acute leukemia, a subgroup of patients with
a marked beneﬁt from the intervention. In addition, the effects on
LVEF were observed, not only among the patients who survived
a septic episode, but also in the other 66 patients, especially in
patients with acute leukemia in which a 5  5.7% intergroup
absolute difference was observed. Finally, a positive trend for the
intervention was also observed in the number of patients with heart
failure or a drop of 10% in LVEF, although the incidence was too
low to preclude deﬁnite conclusions.
We agree with Dr. Spallarossa and colleagues that the antioxi-
dant effect of carvedilol may play an important role in its car-
dioprotective effect (as do their demonstrated antiapoptotic and
pleiotropic effects) and on the importance to correctly treat
hypertensive patients treated with chemotherapy. Because, by
protocol, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and beta-blockers were not allowed in our study,
the 8 hypertensive patients of the control group were treated with
amlodipine; at 6 months follow-up, their mean systolic pressure
was 122  13 mm Hg.
Finally, we understand the safety concern of Dr. Spallarossa et al.
about the rapid initial up-titration of enalapril and carvedilol in
these high-risk patients. This concern was indeed the reason for not
performing a double-blind study with placebo. The protocol used
was safe because all patients had normal LVEF and were treated in-
hospital during frontline therapy under close supervision for a mean
of 1 month, and in no cases did the study treatment prevent the
patients from receiving the optimal chemotherapy regimen. The
tight cooperation we had between hematologists and cardiologists
was certainly the key.*Xavier Bosch, MD
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